2,707
Views
28
CrossRef citations to date
0
Altmetric
RESEARCH ARTICLE

Transdermal delivery of fluvastatin sodium via tailored spanlastic nanovesicles: mitigated Freund's adjuvant-induced rheumatoid arthritis in rats through suppressing p38 MAPK signaling pathway

, , , , &
Pages 1140-1154 | Received 23 Sep 2019, Accepted 24 Oct 2019, Published online: 18 Nov 2019

References

  • Abbas H, Kamel R. (2019). Potential role of resveratrol-loaded elastic sorbitan monostearate nanovesicles for the prevention of UV-induced skin damage. J Liposome Res 1–9.
  • Abdelrahman FE, Elsayed I, Gad MK, et al. (2017). Response surface optimization, ex vivo and in vivo investigation of nasal spanlastics for bioavailability enhancement and brain targeting of risperidone. Int J Pharm 530:1–11.
  • Aboud HM, Hassan AH, Ali AA, Abdel-Razik A-RH. (2018). Novel in situ gelling vaginal sponges of sildenafil citrate-based cubosomes for uterine targeting. Drug Deliv 25:1328–39.
  • Aboud HM, Mahmoud MO, Abdeltawab Mohammed M, et al. (2019). Preparation and appraisal of self-assembled valsartan-loaded amalgamated Pluronic F127/Tween 80 polymeric micelles: boosted cardioprotection via regulation of Mhrt/Nrf2 and Trx1 pathways in cisplatin-induced cardiotoxicity. J Drug Target 1–18.
  • Ahad A, Aqil M, Kohli K, et al. (2012). Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan. Nanomedicine 8:237–49.
  • Ahmed YM, Messiha BA, Abo-Saif AA. (2015). Protective effects of simvastatin and hesperidin against complete Freund's adjuvant-induced rheumatoid arthritis in rats. Pharmacology 96:217–25.
  • Ahmed YM, Messiha BAS, Abo-Saif AA. (2017). Granisetron and carvedilol can protect experimental rats against adjuvant-induced arthritis. Immunopharmacol Immunotoxicol 39:97–104.
  • Akbari V, Abedi D, Pardakhty A, Sadeghi-Aliabadi H. (2015). Release studies on ciprofloxacin loaded non-ionic surfactant vesicles. Avicenna J Med Biotechnol 7:69–75.
  • Al-Kassas R, Wen J, Cheng AE-M, et al. (2016). Transdermal delivery of propranolol hydrochloride through chitosan nanoparticles dispersed in mucoadhesive gel. Carbohydr Polym 153:176–86.
  • Alkilani AZ, McCrudden MT, Donnelly RF. (2015). Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics 7:438–70.
  • Al-Mahallawi AM, Khowessah OM, Shoukri RA. (2017). Enhanced non invasive trans-tympanic delivery of ciprofloxacin through encapsulation into nano-spanlastic vesicles: fabrication, in-vitro characterization, and comparative ex-vivo permeation studies. Int J Pharm 522:157–64.
  • Andersen T, Vanić Ž, Flaten G, et al. (2013). Pectosomes and chitosomes as delivery systems for metronidazole: the one-pot preparation method. Pharmaceutics 5:445–56.
  • Annadurai G, Ling LY, Lee JF. (2008). Statistical optimization of medium components and growth conditions by response surface methodology to enhance phenol degradation by Pseudomonas putida. J Hazard Mater 151:171–8.
  • Arnaud C, Mach F. (2006). Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy. Arthritis Rheum 54:390–2.
  • Bancroft JD, Gamble M. (2008). Theory and practice of histological techniques. Churchill Livingstone: Elsevier Health Sciences.
  • Beutler E, Duron O, Kelly BM. (1963). Improved method for the determination of blood glutathione. J Lab Clin Med 61:882–8.
  • Biesen R, Burmester G, Hiepe F. (2014). Rheumatoid factor or antinuclear antibodies as incidental finding. Internist 55:1157–64.
  • Cavagna L, Boffini N, Cagnotto G, et al. (2012). Atherosclerosis and rheumatoid arthritis: more than a simple association. Mediators Inflamm 2012:1.
  • Cevc G, Blume G. (2003). Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes®. Biochim Biophys Acta 1614:156–64.
  • Cho H-J, Park JW, Yoon I-S, Kim D-D. (2014). Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. Int J Nanomedicine 9:495–504.
  • Das BR, Roy A, Khan FR. (2015). Cartilage oligomeric matrix protein in monitoring and prognostication of osteoarthritis and its utility in drug development. Perspect Clin Res 6:4–9.
  • De Lima LS, Araujo MDM, Quináia SP, et al. (2011). Adsorption modeling of Cr, Cd and Cu on activated carbon of different origins by using fractional factorial design. Chem Eng J 166:881–9.
  • Devaraj GN, Parakh S, Devraj R, et al. (2002). Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci 251:360–5.
  • El Zaafarany GM, Awad GA, Holayel SM, Mortada ND. (2010). Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int J Pharm 397:164–72.
  • El-Helw A-RM, Fahmy UA. (2015). Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers. Int J Nanomedicine 10:5797–804.
  • Elkomy MH, Elmenshawe SF, Eid HM, Ali AM. (2016). Topical ketoprofen nanogel: artificial neural network optimization, clustered bootstrap validation, and in vivo activity evaluation based on longitudinal dose response modeling. Drug Deliv 23:3294–306.
  • ElMeshad AN, Mohsen AM. (2016). Enhanced corneal permeation and antimycotic activity of itraconazole against Candida albicans via a novel nanosystem vesicle. Drug Deliv 23:2115–23.
  • El-Nabarawi MA, Ali AA, Aboud HM, et al. (2016). Transbuccal delivery of betahistine dihydrochloride from mucoadhesive tablets with a unidirectional drug flow: in vitro, ex vivo and in vivo evaluation. Drug Des Devel Ther 10:4031–45.
  • El-Say KM, Abd-Allah FI, Lila AE, et al. (2016). Diacerein niosomal gel for topical delivery: development, in vitro and in vivo assessment. J Liposome Res 26:57–68.
  • Elsherif NI, Shamma RN, Abdelbary G. (2017). Terbinafine hydrochloride trans-ungual delivery via nanovesicular systems: in vitro characterization and ex vivo evaluation. AAPS PharmSciTech 18:551–62.
  • Fahmy AM, El-Setouhy DA, Habib BA, Tayel SA. (2019). Enhancement of transdermal delivery of haloperidol via spanlastic dispersions: entrapment efficiency vs. particle size. AAPS PharmSciTech 20:95.
  • Fahmy UA. (2015). Nanoethosomal transdermal delivery of vardenafil for treatment of erectile dysfunction: optimization, characterization, and in vivo evaluation. Drug Des Devel Ther 9:6129–37.
  • Fukumoto Y, Libby P, Rabkin E, et al. (2001). Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 103:993–9.
  • Gonzalez O, Iriarte G, Rico E, et al. (2010). LC–MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 878:2685–92.
  • Guinedi AS, Mortada ND, Mansour S, Hathout RM. (2005). Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 306:71–82.
  • Hanayama R, Shimizu H, Nakagami H, et al. (2009). Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action. Int J Mol Med 23:581–8.
  • Haruna Y, Morita Y, Yada T, et al. (2007). Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant‐induced arthritis. Arthritis Rheum 56:1827–35.
  • Jury E, Ehrenstein M. (2005). Statins: immunomodulators for autoimmune rheumatic disease? Lupus 14:192–6.
  • Kah J, Wüstenberg A, Keller AD, et al. (2012). Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep 28:1077–83.
  • Kakkar S, Kaur IP. (2011). Spanlastics—a novel nanovesicular carrier system for ocular delivery. Int J Pharm 413:202–10.
  • Kaur R, Ajitha M. (2019). Transdermal delivery of fluvastatin loaded nanoemulsion gel: preparation, characterization and in vivo anti-osteoporosis activity. Eur J Pharm Sci 136:104956.
  • Khallaf RA, Aboud HM, Sayed OM. (2019). Surface modified niosomes of olanzapine for brain targeting via nasal route; preparation, optimization, and in vivo evaluation. J Liposome Res 1–11.
  • Lee C-C, Lee R-P, Subeq Y-M, et al. (2009). Fluvastatin attenuates severe hemorrhagic shock-induced organ damage in rats. Resuscitation 80:372–8.
  • Li J, Yang M, Xu W-R. (2018). Enhanced oral bioavailability of fluvastatin by using nanosuspensions containing cyclodextrin. Drug Des Devel Ther 12:3491–9.
  • Li P, Zheng Y, Chen X. (2017). Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol 8:460.
  • Liu M, Mao W, Guan H, et al. (2011). Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats. Int Immunopharmacol 11:2150–8.
  • Mahmoud MO, Aboud HM, Hassan AH, et al. (2017). Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats. J Control Release 254:10–22.
  • Mathew LE, Rajagopol V, Pushpan CK, Helen A. (2013). Fluvastatin alleviates inflammation and oxidative stress in adjuvant induced arthritic rats by the down regulation of TNF-α and IL-6. Pharmacologia 4:498–506.
  • McCarey DW, Sattar N, McInnes IB. (2005). Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Res Ther 7:55–61.
  • Mokhtar M, Sammour OA, Hammad MA, Megrab NA. (2008). Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm 361:104–11.
  • Niwa S, Totsuka T, Hayashi S. (1996). Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 18:669–75.
  • Ohkawa H, Ohishi N, Yagi K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–8.
  • Paraskevas KI. (2008). Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 27:281–7.
  • Petersen SG, Saxne T, Heinegard D, et al. (2010). Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical training. Osteoarthritis Cartilage 18:34–40.
  • Ruckmani A, Meti V, Vijayashree R, et al. (2018). Anti-rheumatoid activity of ethanolic extract of Sesamum indicum seed extract in Freund's complete adjuvant induced arthritis in Wistar albino rats. J Tradit Complement Med 8:377–86.
  • Ruckmani K, Sankar V. (2010). Formulation and optimization of zidovudine niosomes. AAPS PharmSciTech 11:1119–27.
  • Salem HF, Ahmed SM, Hassaballah AE, Omar MM. (2015). Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study. Drug Des Devel Ther 9:3705–27.
  • Scripture CD, Pieper JA. (2001). Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 40:263–81.
  • Senokuchi T, Matsumura T, Sakai M, et al. (2005). Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway. J Biol Chem 280:6627–33.
  • Shukla P, Dwivedi P, Gupta PK, Mishra PR. (2014). Optimization of novel tocopheryl acetate nanoemulsions for parenteral delivery of curcumin for therapeutic intervention of sepsis. Expert Opin Drug Deliv 11:1697–712.
  • Soulaidopoulos S, Nikiphorou E, Dimitroulas T, Kitas GD. (2018). The role of statins in disease modification and cardiovascular risk in rheumatoid arthritis. Front Med 5:24.
  • Sun H-Y, Hu K-Z, Yin Z-S. (2017). Inhibition of the p38-MAPK signaling pathway suppresses the apoptosis and expression of proinflammatory cytokines in human osteoarthritis chondrocytes. Cytokine 90:135–43.
  • Suresh P, Kavitha CN, Babu SM, et al. (2012). Effect of ethanol extract of Trigonella foenum graecum (Fenugreek) seeds on Freund's adjuvant-induced arthritis in albino rats. Inflammation 35:1314–21.
  • Suzumura K, Yasuhara M, Narita H. (1999). Superoxide anion scavenging properties of fluvastatin and its metabolites. Chem Pharm Bull 47:1477–80.
  • Taal E, Bobietinska E, Lloyd J, et al. (2006). Successfully living with chronic arthritis. The role of the allied health professionals. Clin Rheumatol 25:189–97.
  • Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH. (2015). Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. Int J Pharm 483:77–88.
  • Uchegbu IF, Florence AT. (1995). Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Colloid Interface Sci 58:1–55.
  • Vervoordeldonk MJ, Tak PP. (2002). Cytokines in rheumatoid arthritis. Curr Rheumatol Rep 4:208–17.
  • Waaler E. (2007). On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. 1939. APMIS 115:422–38.
  • Wacker M. (2013). Nanocarriers for intravenous injection—the long hard road to the market. Int J Pharm 457:50–62.
  • Yano M, Ikeda M, Abe KI, et al. (2009). Oxidative stress induces anti‐hepatitis C virus status via the activation of extracellular signal‐regulated kinase. Hepatology 50:678–88.
  • Yoshioka T, Sternberg B, Florence AT. (1994). Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int J Pharm 105:1–6.
  • Zhang Y, Huo M, Zhou J, Xie S. (2010). PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99:306–14.
  • Zhang Z-c, Zhang S-j, Jin B, et al. (2015). Ciclamilast ameliorates adjuvant-induced arthritis in a rat model. Biomed Res Int 2015:786104.
  • Zwerina J, Hayer S, Redlich K, et al. (2006). Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 54:463–72.